13F Holdings
中文EN

NPCE NeuroPace Inc

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1528287 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.9%
TTM net income YoY21.1%
TTM EPS YoY25.3%
Revenue 3-yr CAGR16.3%
Net income 3-yr CAGR—

Margins

Gross margin81.4%
Operating margin-15.4%
Net margin-20.0%
FCF margin-13.1%
EBITDA margin-15.0%

Returns

ROE-126.1%
ROA-18.7%
ROIC (approx.)-19.7%
Asset turnover0.94x

Leverage & solvency

Liabilities / assets87.9%
Debt / equity5.15x
Current ratio5.26x
Interest coverage-2.34x

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$99.99M$79.91M$65.42M$45.52M$45.18M
Cost of revenue$22.77M$20.82M$17.30M$13.03M$11.75M
Gross profit$77.22M$59.09M$48.12M$32.49M$33.44M
R&D expense$27.89M$23.65M$20.78M$21.95M$18.21M
SG&A expense$19.09M$17.43M$54.52M$51.34M$38.96M
Operating income-$16.34M-$21.67M-$27.17M-$40.79M-$23.74M
Interest expense$7.46M$8.80M$8.52M$7.53M$7.41M
Income tax$0————
Net income-$21.46M-$27.14M-$32.96M-$47.08M-$36.08M
EBITDA-$16.10M-$21.46M-$27.00M-$40.53M-$23.44M
EPS (basic)-0.66-0.93-1.27-1.91-2.17
EPS (diluted)-0.66-0.93-1.27-1.91-2.17
Dividends declared per share0.000.000.00——
Weighted avg. shares (diluted)32.72M29.13M25.85M24.59M16.61M
Balance sheet
Cash & equivalents$21.69M$13.55M$18.18M$6.73M$19.31M
Short-term investments$39.37M$39.33M$48.40M$70.80M$96.40M
Receivables$12.94M$12.85M$12.31M$7.48M$7.09M
Inventory$14.86M$13.38M$11.21M$9.71M$7.82M
Current assets$94.07M$81.34M$92.72M$97.71M$132.82M
PP&E, net$1.12M$1.05M$1.00M$1.06M$603,000
Total assets$105.56M$94.65M$107.65M$114.11M$133.56M
Current liabilities$17.81M$15.16M$16.23M$10.98M$9.30M
Short-term debt————$0
Long-term debt$58.88M$59.52M$56.95M$52.91M$49.85M
Total debt$58.88M$59.52M$56.95M$52.91M$49.85M
Total liabilities$86.53M$86.63M$87.00M$79.33M$60.06M
Shareholders' equity$19.03M$8.01M$20.65M$34.78M$73.50M
Net debt$37.19M$45.97M$38.77M$46.19M$30.54M
Shares outstanding33.57M30.15M27.82M25.05M24.45M
Cash flow statement
Operating cash flow-$11.01M-$17.95M-$19.70M-$36.87M-$24.58M
Capital expenditure$332,000$306,000$173,000$603,000$384,000
Free cash flow-$11.34M-$18.25M-$19.87M-$37.47M-$24.96M
Investing cash flow-$332,000$8.99M$23.03M$23.80M-$85.40M
Financing cash flow$19.60M$4.33M$8.13M$490,000$102.53M
Depreciation & amortization$238,000$207,000$172,000$267,000$296,000
Stock-based compensation$11.09M$10.28M$9.56M$8.35M$4.29M
Share buybacks$49.55M$0———

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.